A comparison of plasma versus histologic indices of angiogenic markers in breast cancer

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 4, 2007, Pages 382-388

  Caine, Graham J ^a   Lip, Gregory ^a   Zanetto, Ulyses ^b   Maheshwari, Mahwandra ^b   Stonelake, Paul S ^b   Blann, Andrew D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Flt 1; Tie 2; VEGF

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD CLOTTING; BLOOD LEVEL; BREAST CANCER; BREAST DISEASE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION;

BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, TIE-2; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 37349046351     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000213137.01536.ca     Document Type: Article

References (25)

1. Senger DR, Galli SJ, Dvoral AM, et al. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascetic fluid. Science. 1983;219:983-985.
2. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029-1039.
3. Dirix LY, Vermeulen PB, Pawinski A, et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer. 1997;76:238-245.
4. Takanami I, Tanaka F, Hashizume T, et al. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 1997;17:2811-2814.
5. Clauss M. Functions of the VEGF Receptor-1 (FLT-1) in the Vasculature. Trends Cardiovasc Med. 1998;8:241-245.
6. Schurch H, Risau W. Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development. 1993;119:957-968.
7. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie-2, that disrupts in vivo angiogenesis. Science. 1997;277:55-60.
8. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, et al. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilisation, cell survival, and interaction with other angiogenic growth factors. Lab Invest. 1999;79:213-223.
9. Koga K, Todaka T, Morioka M, et al. Expression of angiopoietin-2 on human glioma cells and its role in angiogenesis. Cancer Res. 2001;61:6248-6254.
10. Currie MJ, Gunningham SP, Turner K, et al. Expression of the angiopoietins and their receptor Tie-2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol. 2002;198:502-510.
11. Caine GJ, Blann AD, Stonelake PS, et al. Plasma angiopoietin-1, angiopoietin-2 and tie-2 in breast and prostate cancer: a comparison with VEGF and flt-1. Eur J Clin Invest. 2003;33:883-890.
12. Garvin S, Nilsson UW, Dabrosin C. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer. 2005;93:1005-1010.
13. Ryden L, Jirstrom K, Bendahl PO, et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol. 2005;23:4695-4704.
14. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769-777.
15. Kassim SK, El-Salahy EM, Fayed ST, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem. 2004;37:363-369.
16. Ludovini V, Sidoni A, Pistola L, et al. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res Treat. 2003;81:159-168.
17. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995;26:86-91.
18. Toi M, Bando H, Ogawa T, et al. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer. 2002;98:14-18.
19. Dales JP, Garcia S, Bonnier P, et al. Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma. Ann Pathol. 2003;23:297-305.
20. Peters KG, Coogan A, Berry D, et al. Expression of Tie2/Tek in breast tumor vasculature provides a new marker for evaluation of tumor angiogenesis. Br J Cancer. 1998;77:51-56.
21. Peters KG, Kontos CD, Lin PC, et al. Functional significance of Tie2 signaling in the adult vasculature. Recent Prog Horm Res. 2004;59:51-71.
22. Toi M, Bando H, Weich HA. Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: a hypothetical consideration. Biomed Pharmacother. 2005;59(Suppl 2): S344-S347.
23. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3:24-40.
24. Nicolini A, Carpi A, Tarro G. Biomolecular markers of breast cancer. Front Biosci. 2006;11:1818-1843.
25. Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist. 2005;10:382-391.